- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04913155
HANSE - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort (HANSE)
HANSE - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort, Population-based Screening Study -Prospective, Randomized Comparator Controlled
Study Overview
Detailed Description
Germany has a long history of offering screening programs for cancers, such as breast, colorectal, and, more recently, cervical and skin cancer. Screening for lung cancer, however, which causes more deaths than any other cancer in men and is the second leading cancer death in women (not far behind breast cancer), has not been implemented to date. Only very recently, Institute for Quality and Efficiency in Healthcare (IQWiG) in a preliminary assessment of low-dose CT screening, concluded that the benefits from screening outweigh potential risks. However, an implementation of a national lung cancer screening program, which would be covered by the general health insurance, will likely not be implemented before 2022.
Nonetheless, the IQWiG report also comments on important criteria for implementing lung cancer screening in Germany using low-dose CT:
- It would be necessary to determine criteria that define a high-risk population. Various risk forecasting models are currently being propagated to enable a more precise selection of high-risk individuals. Their reliability and repeatability needs to be checked.
- Integration of access to a smoking cessation program.
- Quality assurance measures must be taken into account, including standardized protocols for the evaluation of the CT images and the subsequent follow-up checks as well as the invasive diagnostic tissue sampling procedures. The HANSE study is primarily intended as a pilot to provide evidence that a holistic and effective lung cancer screening program can be implemented in Germany and that such a screening program can be integrated in the current infrastructure of certified lung cancer centers.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jens Vogel-Claussen, Prof. Dr.
- Phone Number: +49 511 532 9817
- Email: Vogel-Claussen.Jens@mh-hannover.de
Study Contact Backup
- Name: Heiko Hartleb
- Phone Number: +49 641 94436 241
- Email: heh@alcedis.de
Study Locations
-
-
Niedersachsen
-
Hannover, Niedersachsen, Germany, 30625
- Recruiting
- Medizinische Hochschule Hannover
-
Contact:
- Jens Vogel-Claussen, Prof. Dr.
- Phone Number: +49 511 532 9817
- Email: Vogel-Claussen.Jens@mh-hannover.de
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Germany, 22927
- Recruiting
- LungenClinic Grosshansdorf
-
Contact:
- Martin Reck, Prof. Dr.
- Phone Number: +49 4102 601 2101
- Email: M.Reck@lungenclinic.de
-
Lübeck, Schleswig-Holstein, Germany, 23538
- Recruiting
- Universitätsklinikum Schleswig-Holstein
-
Contact:
- Sabine Bohnet, Dr.
- Phone Number: +49 451 500 45003
- Email: Sabine.Bohnet@uksh.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects aged 55-79 years
- Current or former smokers
- Subjects with calculated risk score PLCOM2012 ≥1.58% (6 yrs.) or NELSON inclusion criteria (current or former smokers [those who had quit ≤10 years ago] who had smoked >15 cigarettes a day for >25 years or >10 cigarettes a day for >30 years).
- Able and willing to give written informed consent In addition, non-qualifying subjects fulfilling inclusion criteria 1 (age), 2 (smoking history) and 4 (consent), but do not meet the inclusion criterion 3 (risk too low) will be asked to volunteer by contributing long-term outcome data informing of the development of lung cancer or death from lung cancer (about n=7100 randomly selected from all 3 centers, low-risk group). These subjects will be contacted via mail after a minimum of 5 year follow up to inquire if they developed lung cancer in the time between their recruitment and present. Non-responders will be followed by local registries and by phone. New lung cancer cases will be verified using official hospital or cancer registry documents.
Exclusion Criteria:
- Comorbidity, which would unequivocally contraindicate either screening or treatment if lung cancer is detected.
- History of chest CT within the past year preceding the invitation.
- Inability to undergo non-contrast CT (e.g. ≥ 200 kg body weight, inability to lie flat).
- Pregnancy
Risk of non-compliance with study procedures.
- Unable to give written consent
- Patient's inability to fill in the questionnaire self-dependent
- Limited knowledge of the German language
- Inability to travel, residents of care facilities, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Reporting group (coronary calcium score and emphysema score)
Coronary calcium score and emphysema score are reported to subjects
|
Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
|
Other: Reporting group (coronary calcium score only)
Only coronary calcium score is reported to subjects
|
Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
|
Other: Reporting group (emphysema score only)
Only emphysema score is reported to subjects
|
Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
|
Other: Non-reporting group
Coronary calcium score and emphysema score are not reported to subjects
|
Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
|
No Intervention: Low-risk group
No CT screening, collection of health data only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary endpoint
Time Frame: 5 years
|
Positive predictive value (PPV) for lung cancer detection with different inclusion methods (NELSON vs. PLCO) after 2 screening rounds.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Key secondary endpoint 1
Time Frame: 1 year
|
Proportion of individuals selected for screening within the high-risk population.
|
1 year
|
Key secondary endpoint 2
Time Frame: 5 years
|
Proportion of lung cancers detected with different inclusion methods (NELSON vs. PLCO) within the overall study population after 5 years.
|
5 years
|
Key secondary endpoint 3
Time Frame: 5 years
|
Proportion of lung cancers detected with in the high-risk population after 5 years.
|
5 years
|
Key secondary endpoint 4
Time Frame: 5 years
|
Specificity within the overall population after 5-year follow-up.
|
5 years
|
Key secondary endpoint 5
Time Frame: 5 years
|
Sensitivity within the overall population after 5-year follow-up.
|
5 years
|
Additional secondary endpoint 1
Time Frame: 1 year
|
Rate of initiation of cardiovascular treatments (in particular lipid-lowering) in the calcium score reporting group vs. the non-reporting group after year 1 of study.
|
1 year
|
Additional secondary endpoint 2
Time Frame: 1 year
|
Efficiency of nodule management algorithms (LungRads1.1 + PanCan) will be evaluated according to the number of patients sorted in the category (a) "Next surveillance scan" AND the number of patients with lung cancer sorted into category (b) "early recall scan", or (c) "diagnostic evaluation".
|
1 year
|
Additional secondary endpoint 3.1
Time Frame: 1 year
|
Success of screening program.
Based on all individuals enrolled.
Definition of success is calculated using Response rate.
|
1 year
|
Additional secondary endpoint 3.2
Time Frame: 1 year
|
Success of screening program.
Based on all individuals enrolled.
Definition of success is calculated using Reliability of PLCO risk scoring (self-reported vs. on site assessment).
|
1 year
|
Additional secondary endpoint 3.3
Time Frame: 1 year
|
Success of screening program.
Based on all individuals enrolled.
Definition of success is calculated using Percentage of subjects receiving an adequate low-dose CT scan and report according to DRG guidelines (number of diagnostic CTs/number of all CTs).
|
1 year
|
Additional secondary endpoint 3.4
Time Frame: 1 year
|
Success of screening program.
Based on all individuals enrolled.
Definition of success is calculated using Percentage of subjects receiving adequate follow-up procedures.
|
1 year
|
Additional secondary endpoint 4.1
Time Frame: 1 year
|
Quality of screening program: CT reading performance (2nd reader vs. CAD vs. AI)
|
1 year
|
Additional secondary endpoint 4.2
Time Frame: 1 year
|
Quality of screening program: Quality of lung nodule management
|
1 year
|
Additional secondary endpoint 4.3
Time Frame: 1 year
|
Quality of screening program: Frequency of detection and management of incidental findings from low dose chest CT (emphysema, coronary heart disease, etc.)
|
1 year
|
Additional secondary endpoint 4.4
Time Frame: 1 year
|
Quality of screening program: LDCT dose management
|
1 year
|
Additional secondary endpoint 5
Time Frame: 1 year
|
Smoking cessation: Success of smoking cessation counseling based on number of participants quitting with or without revealing additional health risks (emphysema score, coronary calcium score or both).
|
1 year
|
Additional secondary endpoint 6.1
Time Frame: 1 year
|
Identification of blood-based biomarkers for early detection of lung tumors: Blood collection and evaluation of various blood-based epigenetic biomarkers in positive LDCT cases with subsequent biopsy on the positive predictive value of the LDCT test.
|
1 year
|
Additional secondary endpoint 6.2
Time Frame: 1 year
|
Identification of exhalation-based biomarkers for early detection of lung tumors: Collection of breath condensate and evaluation of various exhalation-based epigenetic biomarkers in positive LDCT cases with subsequent biopsy on the positive predictive value of the LDCT test.
|
1 year
|
Additional secondary endpoint 7.1
Time Frame: 1 year
|
Cost-effectiveness analysis: Main objectives of the modelling study are to investigate the impact of different components of LDCT lung cancer screening on the long-term all-cause mortality and cost-effectiveness.
Key components include risk score-based selection criteria, nodule management protocols, threshold values of imaging biomarkers for cardio-vascular diseases and COPD, and inclusion of smoking cessation programs (performed by Center for Health Economics Research Hannover (CHERH).
|
1 year
|
Additional secondary endpoint 7.2
Time Frame: 1 year
|
Cost-effectiveness analysis: Comparison of patient recruitment strategies: Cost-effectiveness of register-based mailing campaign vs. GP referrals in terms of recruitment of qualified screening subjects (Center for Health Economics Research Hannover - CHERH).
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Jens Vogel-Claussen, Prof. Dr., Hannover Medical School
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESR-20-20770
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Low-dose CT screening
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía TorácicaNot yet recruitingLung Cancer | Protection Against Malignant Lung Neoplasm (Diagnosis)
-
Groupe Hospitalier de la Region de Mulhouse et...RecruitingLung Cancer | High-Risk CancerFrance
-
Shanghai Changzheng HospitalUnknownCardiovascular Disease | Lung Neoplasms | Chronic Obstructive Pulmonary Disease | Mass ScreeningChina
-
Kyoung Ho Lee, MDSeoul National University Bundang Hospital; Ministry of Health & Welfare, Korea and other collaboratorsCompleted
-
Seoul National University Bundang HospitalGE Healthcare; National Research Foundation of KoreaCompletedAppendicitisKorea, Republic of
-
Yale UniversityAgency for Healthcare Research and Quality (AHRQ)Completed
-
Sang-Won UmNot yet recruitingHealth Risk Behaviors
-
University Hospital, GenevaCompleted
-
Oncology Teaching Hospital, BaghdadEnrolling by invitation
-
Hospices Civils de LyonCompletedTelangiectasia, Hereditary Hemorrhagic | Rendu Osler DiseaseFrance